STAT
DECEMBER 7, 2023
In 1997, Celgene obtained a key patent for what would become a blockbuster blood cancer treatment, giving it a monopoly until 2019. But like any pharmaceutical company with an eye toward the future, Celgene continued to seek other ways to wring profits from its development work.
STAT
NOVEMBER 18, 2022
… Pharmaceutical companies could be made to disclose prices and deals for products they make to fight future global health emergencies, under new rules that would govern a World Health Organization-backed pandemic accord , Reuters reports. As of 2019, about 1.9 Or you may want to take stock of your life. But be safe.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
SEPTEMBER 25, 2023
NMR relaxation methods distinguish between components (phases or compounds) that have different molecular mobilities For monoclonal antibodies, identification methodologies can employ chromatography, spectroscopy, isoelectric focusing, capillary electrophoresis and peptide mapping techniques. 2019; 57(10): 794–804. 2019; 57(10): 873–7.
European Pharmaceutical Review
AUGUST 17, 2022
billion by 2030, expanding at a compound annual growth rate (CAGR) of 7.2 Pharmaceutical companies globally are significantly investing in R&D. For Biogen, this was a 75 percent increase in R&D expenditure from 2019. percent from its 2022 value of $35.1 billion and Biogen’s approximately $4 billion.
European Pharmaceutical Review
FEBRUARY 21, 2023
After the substance became legal in the UK in 2018, pharmaceutical companies have faced numerous obstacles to attain a fairer position in the industry. Advising companies, he emphasised that those “manufacturing cannabis-based medicines should not underestimate the scale of the challenge.”
Pharmaceutical Technology
JANUARY 10, 2023
GlobalData expects that the T2D market will see significant growth from 2019–29, with the 9MM having a total of $45.9 billion in sales in 2019, increasing to $136.2 billion in 2029, with drug sales almost doubling at a compound annual growth rate (CAGR) of 11.5%.
European Pharmaceutical Review
MAY 2, 2023
In 2019, the pharmaceutical industry spent $83 billion on R&D, which is about 10 times what the industry spent per year in the 1980s, 4 yet the average duration to develop a new medicine is still around 10-15 years. About the authors Dr Nils Eckardt joined BeiGene in February 2019 as Vice President, Medical Affairs, Europe.
Expert insights. Personalized for you.
116 
Let's personalize your content